EMA Recommends Granting a Marketing Authorisation for Capmatinib
It is intended for treatment of patients with advanced NSCLC harbouring alterations leading to METex14 skipping
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1548 results
Antitumour Activity and Favourable Safety Demonstrated After Treatment with Nivolumab and Ipilimumab Combined with SBRT for Refractory Metastatic Pancreatic Cancer
Findings from the CheckPAC study
Remote Monitoring of Patients Treated with Oral Anticancer Drugs Improves Patient Care Experience and Optimises Healthcare Resources
Findings from a randomised phase III CAPRI study
Shortening Duration of Adjuvant Treatment from 6 to 3 Months Did Not Compromise Efficacy in Asian Patients with Stage III Colon Cancer
Findings from the phase III ACHIEVE study
FDA Grants Regular Approval to fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HER2-positive Breast Cancer
It is indicated for the treatment of patients who have received a prior anti-HER2-based regimen
EMA Recommends Extension of Therapeutic Indications for Pembrolizumab
New indication concerns a neoadjuvant and adjuvant treatment of adult patients with triple negative breast cancer at high risk of recurrence
Imiquimod is a Safe and Effective Alternative to Surgery for Vulvar High-Grade Squamous Intraepithelial Lesions
Findings from a randomised, phase III, non-inferiority study
EMA Recommends Extension of Therapeutic Indications for Tisagenlecleucel
New indication concerns the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy
Neoadjuvant Nivolumab Plus Chemotherapy Results in Significantly Longer Event-Free Survival in Patients with Resectable NSCLC
Higher percentage of patients with a pathological complete response also achieved with neoadjuvant nivolumab plus chemotherapy
Triplet Therapy with ADT, Docetaxel and Abiraterone Plus Prednisone Improves Survival in De Novo Metastatic Castration-Sensitive Prostate Cancer
Findings from the PEACE-1 study
EMA Recommends Extension of Therapeutic Indications for Cabozantinib
New indication concerns the treatment of patients with differentiated thyroid carcinoma refractory or not eligible to radioactive iodine
Increased Risk of Cancer in Early Life Among Individuals with Autism Spectrum Disorders
Increased cancer risk among individuals with autism is likely attributable to co-occurring intellectual disability and/or birth defects